-
2 weeks ago | 
insights.citeline.com | Joseph Haas |Xu Hu |Anju Ghangurde |Lisa Takagi
Asia Deal Watch: Lilly Partners With Rznomics On Hearing LossPlus deals involving Minghui/Qilu, LENZ/Lotus, Amicus/Dimerix, Sanofi/Dr. Reddy’s, Henlius/Lotus, Apnimed/Desitin, Formosa/Saval, DAAN/GC Cell, VelaVigo/Ollin and Sol-Gel/Mayne.
-
3 weeks ago | 
insights.citeline.com | Dexter Yan |Xu Hu
China Biopharma Podcast - 14 May 2025 (Chinese Language)Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage. join or China-based editors Dexter Yan and Xu Hu in their latest Chinese language podcast • Source: Citeline/Shutterstock
-
Feb 5, 2025 | 
insights.citeline.com | Joseph Haas |Dexter Yan |Xu Hu |Vibha Ravi
Deal Watch: Novo Nordisk, IMMvention To Partner On Sickle Cell DiseasePlus deals involving Vanda/AnaptysBio, OS Therapies/Ayala, Leveragen/Moonlight Bio, Lantheus/Evergreen, Exicure/GPCR, Arrivent/Lepu, InnoCare/KeyMed/Prolium and more.
-
Jan 15, 2025 | 
insights.citeline.com | Xu Hu
New China Policies Aim To Improve Market AccessPlus R&D Support And Continue Open-upChina’s State Council has released a wide-ranging set of policy incentives intended to eliminate regulatory barriers and improve market access for innovative drugs. China's State Council on 3 January released a series of encouraging measures for reforms and quality development in the biopharma sector. (Shutterstock)
-
Jan 14, 2025 | 
insights.citeline.com | Xu Hu
XGene’s Non-Opioid Pain Contender Shows Pre-/Post-Op PromisePotential Competitor For Vertex? XGene's pain candidate has shown positive results in a US bunionectomy trial and the Chinese company is also eyeing chronic and cancer pain indications for its contender, which may provide a competitor to Vertex's suzetrigine. XGene Pharmaceutical's non-opioid, dual-targeting analgesic XG005 showed positive topline Phase IIb/III results in acute pain. (Shutterstock)
-
Jan 7, 2025 | 
insights.citeline.com | Xu Hu
Innovative Drugs At Center Of China’s 2024 Regulatory Efforts Review Process, Pricing And Insurance On Agenda The policies for China’s biopharma industry in 2024 centered around innovative small molecules, biologics and cell and gene therapies. Regulation changes for the industry in 2025 could be a continuation of that. China's regulations for the biopharma industry centered around innovative drugs in 2024; in 2025, it may be a continuation of that. (Shutterstock)
-
Dec 12, 2024 | 
insights.citeline.com | Xu Hu
China’s Basic Health Insurance For Innovative Drugs Needs ReformCommercial Schemes A New OptionChina is advocating reforms to health insurance, particularly the wider use of commercial schemes, for reasons to support innovative drug development. China is reforming its health insurance payment method, especially commercial health insurance. (Shutterstock)
-
Dec 10, 2024 | 
insights.citeline.com | Xu Hu
Belief BioMed Eyes Rare Disorders With AAV-Based Gene TherapiesNew Hemophilia B Results At ASHChina's Belief BioMed presented promising new Phase III results at ASH for its AAV gene therapy for hemophilia B, although the wider China CGT space continues to be dominated by oncology. Belief BioMed focuses on AAV-based gene therapies for rare disorders. (Shutterstock)
-
Dec 5, 2024 | 
insights.citeline.com | Xu Hu
Enhertu Among Drugs Included In Annual China NRDL UpdateLocal Companies Dominate But No CAR-Ts The majority of new drugs added to the latest revision of China's NRDL were developed by Chinese companies, although half of the global top 20 pharmas also have new entries. Bispecifics were included for the first time but no CAR-Ts made the cut. China's National Healthcare Security Administration updated the national reimbursement drug list towards the end of November. (Shutterstock)
-
Nov 26, 2024 | 
insights.citeline.com | Xu Hu
Looking Beyond BioNTech/Biotheus To Future Potential China Deals Bispecifics/ADCs To Attract More Foreign Interest? BioNTech and Biotheus’s recent acquisition deal and the current tough funding environment for Chinese biotechs may point to further potential transactions at attractive valuations. Bispecific antibodies and ADCs in oncology are possible targets for cross-border deals.
